Blunted sympathetic response in diabetic patients with decompensated congestive heart failure

A J Burger1, D Aronson

  • 1Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, West Campus Noninvasive Cardiology Laboratory, Baker-3 1 Deaconess Road, Boston, MA 02215, USA. aburger@caregroup.harvard.edu

Insights

Diabetic patients with heart failure show a reduced sympathetic response. This blunted sympathetic activation may hinder the heart

Area of Science:

  • Cardiology
  • Endocrinology
  • Neuroscience

Background:

  • Diabetes significantly increases heart failure risk and worsens prognosis.
  • Heart failure involves autonomic and neurohormonal changes detrimental to the heart.
  • Altered neurohumoral function may explain poor outcomes in diabetic heart failure patients.

Purpose of the Study:

  • To investigate neurohormonal and autonomic differences in heart failure patients with and without diabetes.
  • To explore the impact of diabetes on heart failure pathophysiology.

Main Methods:

  • Studied 88 decompensated heart failure patients.
  • Assessed neurohormonal profiles (norepinephrine, aldosterone, etc.) and cytokine levels.
  • Performed 24-h Holter monitoring to calculate heart rate variability indices.

Main Results:

  • Diabetic patients had significantly lower norepinephrine levels compared to non-diabetic patients.
  • Heart rate variability showed reduced sympathetic modulation (low-frequency power) in diabetics.
  • No significant differences in parasympathetic modulation indices were observed between groups.

Conclusions:

  • Diabetes mellitus is associated with a blunted sympathetic response during heart failure decompensation.
  • Impaired sympathetic activation in diabetic heart failure may compromise myocardial compensation.
  • This blunting could contribute to the higher incidence of symptomatic heart failure in diabetic individuals.
Abstract

Related Concept Videos

Disorders of the Autonomic Nervous System01:18

Disorders of the Autonomic Nervous System

The autonomic nervous system (ANS) is an intricate network of nerves that controls functions such as the regulation of heart rate, digestion, and blood pressure regulation. When this system malfunctions, it can lead to various disorders that affect multiple bodily functions. One common feature of many autonomic disorders is the involvement of smooth blood vessels, which play a crucial role in regulating blood flow throughout the body.
Raynaud's disease, also known as Raynaud's phenomenon, is a...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...